Why it matters
The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
Project record
At a glance
- Company
- Amgen
- Industry
- Pharmaceuticals
- Location
- West Greenwich, Rhode Island
- Investment
- $200.0M
- Permanent jobs announced
- 150
- Status
- Operational
- Announced
- Apr 10, 2018
- Operations began
- January 2022
- Added to tracker
- Aug 14, 2026
Sources
Official references
- Initial Rhode Island announcement https://www.ri.gov/press/view/32953
- Investment revision and groundbreaking https://www.amgen.com/newsroom/press-releases/2018/07/amgen-breaks-ground-on-next-generation-biomanufacturing-plant-in-rhode-island
- FDA approval and operational evidence https://www.amgen.com/responsibility/reporting-and-metrics/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/responsibility/amgen-2021-esg-report.pdf
Related
Other projects to know
Back to the tracker/projects/amgen-west-greenwich-next-generation-biomanufacturing-plant